Showing results (591-600 of 661) with videos related to

Sort By:
Pageof 67
Oncogene|October 25, 2018
Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerSteve Wagner, Georgios Vlachogiannis, Alexis De Haven Brandon, et al.
Nature Structural & Molecular Biology|April 17, 2007
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaDavid Cunningham, Dennis E Danley, Kieran F Geoghegan, et al.
The Lancet. Oncology|November 22, 2012
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, et al.
The New England Journal of Medicine|February 2, 2022
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell CarcinomaYuichiro Doki, Jaffer A Ajani, Ken Kato, et al.
JAMA Surgery|November 15, 2013
Processes of care in the multidisciplinary treatment of gastric cancer: results of a RAND/UCLA expert panelSavtaj S Brar, Alyson L Mahar, Lucy K Helyer, et al.
The Lancet. Oncology|September 30, 2017
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trialDaniel V T Catenacci, Niall C Tebbutt, Irina Davidenko, et al.
Lancet (London, England)|November 30, 2015
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trialAndrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2019
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trialRaghav Sundar, Alvin Ng, Hermioni Zouridis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 11, 2018
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trialLi-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, et al.
The Lancet. Oncology|March 6, 2017
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialGary Middleton, Daniel H Palmer, William Greenhalf, et al.
Pageof 67